Mp70-13 Factors That Define the Poor Outcomes for Black Americans With Bladder Cancer: Does Time to Treatment Contribute?

You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes III (MP70) 1 May 2024MP70-13 FACTORS THAT DEFINE THE POOR OUTCOMES FOR BLACK AMERICANS WITH BLADDER CANCER: DOES TIME TO TREATMENT CONTRIBUTE? Oluwaseun O. Orikogbo, Shan Wu, Michael G. Stencel, Mitchell B. Alameddine, Daisy Obiora, Danielle Sharbaugh, Jonathan G. Yabes, Benjamin J. Davies, and Bruce L. Jacobs Oluwaseun O. OrikogboOluwaseun O. Orikogbo, Shan WuShan Wu, Michael G. StencelMichael G. Stencel, Mitchell B. AlameddineMitchell B. Alameddine, Daisy ObioraDaisy Obiora, Danielle SharbaughDanielle Sharbaugh, Jonathan G. YabesJonathan G. Yabes, Benjamin J. DaviesBenjamin J. Davies, and Bruce L. JacobsBruce L. Jacobs View All Author Informationhttps: //doi. org/10. 1097/01. JU. 0001008796. 84999. 75. 13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Black patients diagnosed with bladder cancer have been found to have worse outcomes than their White counterparts. Prior studies have elucidated factors contributing to the disparity in outcomes: stage at presentation, access to care, and treatment decision making. The primary objective of our analysis was to further explore potential racial disparities between these two groups by investigating the time to treatment. METHODS: Using SEER-Medicare data, we identified bladder cancer patients who either underwent cystectomy (with or without neoadjuvant chemotherapy) or trimodal therapy. We compared the demographic characteristics of patients in the White and Black populations and calculated the time duration (in days) from diagnosis to initial treatment. We utilized the Kaplan-Meier survival curve and executed a log-rank test to conduct the statistical analysis. RESULTS: We studied 2, 120 patients who were diagnosed with bladder cancer from 2008 to 2017. Black patients had a higher prevalence of unmarried or unknown marital status (69% vs. 36%, p<0. 001). A greater proportion of Black patients resided in areas with lower education attainment (18% vs. 10%, p=0. 04) and had lower median household incomes (<40, 000) (38% vs. 14%, p<0. 001). Black patients were more inclined to receive trimodal therapy (54% vs. 35%) and less likely to undergo cystectomy (47% vs. 65%). Our analysis, both overall and when stratified by treatment type, revealed no statistically significant racial disparities in the time for treatment initiation between Black and White populations. CONCLUSIONS: There were no statistically significant differences between these two racial groups in their time to treatment, regardless of the treatment approach chosen. Our study re-demonstrated social factors that have previously been found to contribute to Black patients' worse outcomes for bladder cancer treatment. There continues to be a difference in treatment outcomes and future studies should tease out the contributing factors with aims of developing interventions. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc. FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1133 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc. Metrics Author Information Oluwaseun O. Orikogbo More articles by this author Shan Wu More articles by this author Michael G. Stencel More articles by this author Mitchell B. Alameddine More articles by this author Daisy Obiora More articles by this author Danielle Sharbaugh More articles by this author Jonathan G. Yabes More articles by this author Benjamin J. Davies More articles by this author Bruce L. Jacobs More articles by this author Expand All Advertisement PDF downloadLoading. . .